The Study of Drotrecogin Alfa (Activated) in Adult Patients With Severe Sepsis at a Low Risk of Death

• Status: Completed
• Trial end date: 2005-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Adult Patients with Severe Sepsis

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Drotrecogin alfa activated; Protein C

Criteria

Inclusion Criteria:

• Adult patients with recent onset of severe sepsis or presence of a suspected or proven infection, and at least one induced organ dysfunction.

Exclusion Criteria:

• Are indicated for the treatment with drotrecogin alfa (activated) under the applicable label in the investigative site country.

• Are contraindicated for treatment with drotrecogin alfa (activated) under the applicable label in the investigative site country.

• Platelet count less than 30,000/mm3.